Oculis (NASDAQ:OCS) Issues Quarterly Earnings Results, Misses Estimates By $0.28 EPS

Oculis (NASDAQ:OCS) released its earnings results on Tuesday. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.28), Zacks reports. Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%.

Oculis Stock Up 0.5 %

Shares of OCS stock traded up $0.10 during mid-day trading on Tuesday, reaching $18.40. 59,598 shares of the company were exchanged, compared to its average volume of 87,312. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02. The business’s 50 day simple moving average is $20.79 and its 200 day simple moving average is $16.82. The company has a market capitalization of $745.27 million, a P/E ratio of -9.53 and a beta of 0.01. Oculis has a fifty-two week low of $10.55 and a fifty-two week high of $23.08.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Chardan Capital restated a “buy” rating and set a $28.00 price objective on shares of Oculis in a report on Tuesday, January 7th. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Oculis in a research note on Monday, January 6th.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.